Droplet Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Droplet Biosciences, Inc. - overview
Established
2021
Location
Melrose, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and co-founded by Theresa Tribble (CEO) and Stan Lapidus along with the scientific co-founders Jose P. Zevallos and Aadel Chaudhuri in 2021, Droplet Biosciences, Inc operates as a biotechnology platform that engages in diagnosing cancer using bioinformatics. In March 2023, the firm raised USD 8 million in seed funding led by investor The Engine. The company as of April 2023, has developed a non-invasive liquid biopsy technique called Lymph to identify the risk of recurrence of cancer enabling medical practitioners to make post-operative treatment decisions and plans for every individual patient.
Under this technique, lymphatic fluid is collected from surgical drain fluid after tumor resection or surgery, and the fluid is rich in T-cells, proteins, and other biomarkers, assesses metastatic risk, and offers insights into the body’s immune response to cancer. The company plans to utilize its March 2023 funding to establish proof of concept for its Lymph technology.
Current Investors
Engine Ventures
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Oncology/Cancer Treatment
Website
www.dropletbiosci.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.